MORE - New York Times
"Data presented at American Academy of Neurology Annual Meeting
also Show Impact on Measures of Visual Function and Disability
Progression
Biogen Idec (BIIB) and Elan Corporation, plc (ELN)
announced today that in Phase III multiple sclerosis (MS) studies
TYSABRI(R) (natalizumab) showed significant effects on pre-specified
health-related quality of life (QoL) measures, in addition to those
previously reported on disability progression, relapse rate and MRI.
Data presented this week at the annual meeting of the American Academy
of Neurology in San Diego, CA also showed a significant impact on
additional pre-specified measures of disability progression, including
visual and cognitive function......"
